Status:
WITHDRAWN
AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.
Eligibility Criteria
Inclusion
- Healthy volunteers
- Females must be of non-childbearing potential.
Exclusion
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product.
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months (if half-life was \< 24 hours) of the first administration of study drug
- Plasma or blood product donation within one month of screening or any blood donation/blood loss \> 500mL during the 3 months prior to screening.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00963365
Start Date
November 1 2008
End Date
March 1 2010
Last Update
October 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Overland Park, Kansas, United States